{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:47:56Z","timestamp":1760147276698,"version":"build-2065373602"},"reference-count":24,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002704","name":"Spanish Association against Cancer","doi-asserted-by":"publisher","award":["GC16173472GARC"],"award-info":[{"award-number":["GC16173472GARC"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Unlike classical RAS genes, oncogenic mutations on RRAS2 are seldomly found in human cancer. By contrast, RRAS2 is frequently found overexpressed in a number of human tumors, including B and T cell lymphomas, breast, gastric, head and neck cancers. In this regard, we have recently shown that overexpression of wild-type RRAS2 drives the formation of both chronic lymphocytic leukemia (CLL) and breast cancer in mice. In support for the relevance of overexpression of wild type RRAS2 in human cancer, we have found that RRAS2 expression is influenced by the presence of a specific single nucleotide polymorphism (SNP) located in the 3\u2019-untranslated region (UTR) of the RRAS2 mRNA. Perhaps more importantly, the presence of the alternate C, rather than the G allele, at the RRAS2 SNP designated as rs8570 is also associated with worse patient prognosis in CLL. This indicates that the detection of this SNP allelic variants can be informative to predict RRAS2 expression levels and disease long-term evolution in patients. Here, we describe a polymerase chain reaction (PCR)-based method that facilitates the rapid and easy determination of G and C allelic variants of the SNP. Using this approach, we confirm that the C allelic variant is associated with higher expression levels of RRAS2 transcripts and poor patient prognosis. However, we have also found that expression of the C allelic variants correlates with better response to ibrutinib, a Bruton kinase inhibitor commonly used in CLL treatments. This suggests that this method for detecting the RRAS2 rs8570 SNP might be a useful as a tool to predict both patient prognosis and response to targeted therapy in CLL.<\/jats:p>","DOI":"10.3390\/cancers15030644","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T02:52:21Z","timestamp":1674183141000},"page":"644","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An Optimized Single Nucleotide Polymorphism-Based Detection Method Suggests That Allelic Variants in the 3\u2019 Untranslated Region of RRAS2 Correlate with Treatment Response in Chronic Lymphocytic Leukemia Patients"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9985-6762","authenticated-orcid":false,"given":"Alejandro","family":"Hortal","sequence":"first","affiliation":[{"name":"Immune System Development and Function Program, Centro Biolog\u00eda Molecular Severo Ochoa, Consejo Superior de Investigaciones Cient\u00edficas (CSIC)-Universidad Aut\u00f3noma de Madrid, 28049 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Lacuna","sequence":"additional","affiliation":[{"name":"Immune System Development and Function Program, Centro Biolog\u00eda Molecular Severo Ochoa, Consejo Superior de Investigaciones Cient\u00edficas (CSIC)-Universidad Aut\u00f3noma de Madrid, 28049 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3701-7901","authenticated-orcid":false,"given":"Claudia","family":"Cifuentes","sequence":"additional","affiliation":[{"name":"Immune System Development and Function Program, Centro Biolog\u00eda Molecular Severo Ochoa, Consejo Superior de Investigaciones Cient\u00edficas (CSIC)-Universidad Aut\u00f3noma de Madrid, 28049 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3819-4846","authenticated-orcid":false,"given":"Miguel","family":"Alcoceba","sequence":"additional","affiliation":[{"name":"Departamento de Hematolog\u00eda, Hospital Universitario de Salamanca (HUS-IBSAL), 37007 Salamanca, Spain"},{"name":"Centro de Investigaci\u00f3n del C\u00e1ncer, Instituto de Biolog\u00eda Molecular y Celular del C\u00e1ncer, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer, Centro Biolog\u00eda Molecular Severo Ochoa, Consejo Superior de Investigaciones Cient\u00edficas (CSIC), Universidad de Salamanca, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9398-6072","authenticated-orcid":false,"given":"Xos\u00e9 R.","family":"Bustelo","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n del C\u00e1ncer, Instituto de Biolog\u00eda Molecular y Celular del C\u00e1ncer, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer, Centro Biolog\u00eda Molecular Severo Ochoa, Consejo Superior de Investigaciones Cient\u00edficas (CSIC), Universidad de Salamanca, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Departamento de Hematolog\u00eda, Hospital Universitario de Salamanca (HUS-IBSAL), 37007 Salamanca, Spain"},{"name":"Centro de Investigaci\u00f3n del C\u00e1ncer, Instituto de Biolog\u00eda Molecular y Celular del C\u00e1ncer, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer, Centro Biolog\u00eda Molecular Severo Ochoa, Consejo Superior de Investigaciones Cient\u00edficas (CSIC), Universidad de Salamanca, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balbino","family":"Alarc\u00f3n","sequence":"additional","affiliation":[{"name":"Immune System Development and Function Program, Centro Biolog\u00eda Molecular Severo Ochoa, Consejo Superior de Investigaciones Cient\u00edficas (CSIC)-Universidad Aut\u00f3noma de Madrid, 28049 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/s41571-019-0239-8","article-title":"Chronic Lymphocytic Leukaemia: From Genetics to Treatment","volume":"16","author":"Bosch","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA. Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic Lymphocytic Leukaemia: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","article-title":"Chronic Lymphocytic Leukaemia","volume":"391","author":"Hallek","year":"2018","journal-title":"Lancet"},{"key":"ref_5","unstructured":"(2022, September 16). Chronic Lymphocytic Leukemia\u2013Cancer Stat Facts, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1002\/cncr.31674","article-title":"Adult Leukemia Survival Trends in the United States by Subtype: A Population-Based Registry Study of 370,994 Patients Diagnosed during 1995\u20132009","volume":"124","author":"Bailey","year":"2018","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Cohen, J.A., Bomben, R., Pozzo, F., Tissino, E., H\u00e4rzschel, A., Hartmann, T.N., Zucchetto, A., and Gattei, V. (2020). An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy. Cancers, 12.","DOI":"10.3390\/cancers12040894"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.4049\/jimmunol.179.7.4335","article-title":"Natural Phosphorylation of CD5 in Chronic Lymphocytic Leukemia B Cells and Analysis of CD5-Regulated Genes in a B Cell Line Suggest a Role for CD5 in Malignant Phenotype1","volume":"179","author":"Marteau","year":"2007","journal-title":"J. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.it.2013.07.002","article-title":"B Cell Receptor Signaling in Chronic Lymphocytic Leukemia","volume":"34","author":"Burger","year":"2013","journal-title":"Trends Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1038\/sj.onc.1202517","article-title":"TC21 and Ras Share Indistinguishable Transforming and Differentiating Activities","volume":"18","author":"Graham","year":"1999","journal-title":"Oncogene"},{"key":"ref_11","first-page":"4108","article-title":"Aberrant Function of the Ras-Related Protein TC21\/R-Ras2 Triggers Malignant Transformation","volume":"14","author":"Graham","year":"1994","journal-title":"Mol. Cell. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/ni.1749","article-title":"Essential Function for the GTPase TC21 in Homeostatic Antigen Receptor Signaling","volume":"10","author":"Delgado","year":"2009","journal-title":"Nat. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"eaal1506","DOI":"10.1126\/scisignal.aal1506","article-title":"R-Ras2 Is Required for Germinal Center Formation to Aid B Cells during Energetically Demanding Processes","volume":"11","author":"Mendoza","year":"2018","journal-title":"Sci. Signal."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.ajhg.2019.04.013","article-title":"Activating Mutations of RRAS2 Are a Rare Cause of Noonan Syndrome","volume":"104","author":"Capri","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.ajhg.2019.04.014","article-title":"Germline-Activating RRAS2 Mutations Cause Noonan Syndrome","volume":"104","author":"Niihori","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1365-4632.2010.04846.x","article-title":"Greater Expression of TC21\/R-Ras2 in Highly Aggressive Malignant Skin Cancer","volume":"50","author":"Lee","year":"2011","journal-title":"Int. J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1600-0714.2009.00854.x","article-title":"Clinical Significance of TC21 Overexpression in Oral Cancer","volume":"39","author":"Macha","year":"2010","journal-title":"J. Oral Pathol. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000087283","article-title":"TC21\/R-Ras2 Upregulation in Esophageal Tumorigenesis: Potential Diagnostic Implications","volume":"69","author":"Sharma","year":"2005","journal-title":"Oncology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12943-022-01496-x","article-title":"Overexpression of Wild Type RRAS2, without Oncogenic Mutations, Drives Chronic Lymphocytic Leukemia","volume":"21","author":"Hortal","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41598-019-38581-z","article-title":"Cost-Effective and Robust Genotyping Using Double-Mismatch Allele-Specific Quantitative PCR","volume":"9","author":"Lefever","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11523-019-00635-7","article-title":"Inhibiting Bruton\u2019s Tyrosine Kinase in CLL and Other B-Cell Malignancies","volume":"14","author":"Lucas","year":"2019","journal-title":"Target. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1200\/EDBK_279099","article-title":"Current Perspectives on Therapy for Chronic Lymphocytic Leukemia","volume":"40","author":"Awan","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/carcin\/bgs407","article-title":"Association between Functional Polymorphisms in Genes Involved in the MAPK Signaling Pathways and Cutaneous Melanoma Risk","volume":"34","author":"Liu","year":"2013","journal-title":"Carcinogenesis"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1038\/ncomms4881","article-title":"Contribution of the R-Ras2 GTP-Binding Protein to Primary Breast Tumorigenesis and Late-Stage Metastatic Disease","volume":"5","author":"Larive","year":"2014","journal-title":"Nat. Commun."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/3\/644\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:11:27Z","timestamp":1760119887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/3\/644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["cancers15030644"],"URL":"https:\/\/doi.org\/10.3390\/cancers15030644","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2023,1,19]]}}}